Please login to the form below
Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon
He will be the US biopharma's chairman of board of directors
Former GlaxoSmithKline chief executive Jean-Pierre Garnier has been appointed chairman of board of directors at US-based clinical-stage biopharmaceutical company Alzheon.
The firm focuses on brain health, memory and ageing and its lead product is an oral amyloid aggregation inhibitor that targets Alzheimer's disease.
Alzheon's founder, president and chief executive officer Martin Tolar said: “JP will provide invaluable insights and guidance as we advance our lead oral amyloid aggregation inhibitor, ALZ-801, into a phase III clinical programme targeting a genetically-defined Alzheimer's disease population, and execute on our long-term strategy to bring innovative therapies to patients with neurodegenerative disorders.”
Garnier served as SmithKline Beecham's chief executive officer, having joined the company in 1990 as president of pharmaceuticals for North America.
He subsequently became GSK's first CEO following its formation from the merger of Glaxo Wellcome and SmithKline Beecham in 2001 and he held that position until in 2008.
Garnier then became chief executive officer of Pierre Fabre Laboratories and chairman of biotechnology company Cerenis.
He is currently chairman of the board of directors for Swiss biopharmaceutical company Actelion.
Subscribe to our email news alerts
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Seqera Labs and Genomics England partner to progress genomic research
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s RSV vaccine approved by FDA for older adults
No results were found
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
Latest intelligence
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
- Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
- Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...
